New pill targets stubborn leukemia cells in early trial
NCT ID NCT04914845
Summary
This early-stage study tested the safety and highest tolerable dose of a new oral drug called KPT-9274. It involved 16 adults with acute myeloid leukemia that had returned or stopped responding to previous treatments. The main goal was to see if the drug was safe and to find the right dose for future studies, as it works by targeting a specific pathway that fuels the stubborn leukemia cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.